Andere Kunden interessierten sich auch für
![Pharmaceutical Price Regulation: Public Perception, Economic Realities, and Empirical Evidence]( "Pharmaceutical Price Regulation: Public Perception, Economic Realities, and Empirical Evidence")
Pharmaceutical Price Regulation: Public Perception, Economic Realities, and Empirical Evidence13,99 €![Corporate Social Responsibility and the Investor]( "Corporate Social Responsibility and the Investor")
Corporate Social Responsibility and the Investor15,99 €![Reports and Minutes of Evidence ... [and Appendices, Charts, and Indexes ...]; Volume 1]( "Reports and Minutes of Evidence ... [and Appendices, Charts, and Indexes ...]; Volume 1")
Reports and Minutes of Evidence ... [and Appendices, Charts, and Indexes ...]; Volume 128,99 €![Restoring Trust in Governance: India's 2020's Challenge]( "Restoring Trust in Governance: India's 2020's Challenge")
Restoring Trust in Governance: India's 2020's Challenge17,99 €![Coffee, Society, and Power in Latin America]( "Coffee, Society, and Power in Latin America")
Coffee, Society, and Power in Latin America40,99 €![Cost Shifting in Health Care: Separating Evidence from Rhetoric]( "Cost Shifting in Health Care: Separating Evidence from Rhetoric")
Cost Shifting in Health Care: Separating Evidence from Rhetoric17,99 €![The Labour Question: An Epitome of the Evidence and the Report of the Royal Commission on Labour]( "The Labour Question: An Epitome of the Evidence and the Report of the Royal Commission on Labour")
The Labour Question: An Epitome of the Evidence and the Report of the Royal Commission on Labour26,99 €
![Reports and Minutes of Evidence ... [and Appendices, Charts, and Indexes ...]; Volume 1](https://bilder.buecher.de/produkte/67/67178/67178381m.jpg "Reports and Minutes of Evidence ... [and Appendices, Charts, and Indexes ...]; Volume 1")
Includes papers that constitute the largest firm-level corporate governance analysis undertaken across Latin American countries. The datasets in this book allow the researchers to conclude that companies with better firm-level governance practices or with listings in US markets are given higher valuations and can raise capital at a lower cost.